Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Combination Therapy	STARTED	MB02 (Bevacizumab Biosimilar Drug)	315
Combination Therapy	STARTED	EU-approved Avastin®	312
Combination Therapy	COMPLETED	MB02 (Bevacizumab Biosimilar Drug)	207
Combination Therapy	COMPLETED	EU-approved Avastin®	220
Combination Therapy	NOT COMPLETED	MB02 (Bevacizumab Biosimilar Drug)	108
Combination Therapy	NOT COMPLETED	EU-approved Avastin®	92
Monotherapy	STARTED	MB02 (Bevacizumab Biosimilar Drug)	207
Monotherapy	STARTED	EU-approved Avastin®	220
Monotherapy	COMPLETED	MB02 (Bevacizumab Biosimilar Drug)	68
Monotherapy	COMPLETED	EU-approved Avastin®	74
Monotherapy	NOT COMPLETED	MB02 (Bevacizumab Biosimilar Drug)	139
Monotherapy	NOT COMPLETED	EU-approved Avastin®	146

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03296163/flow